The Alzheimer’s drug data released Tuesday night aren’t only going to be transformative for Biogen, which has been struggling to get love from investors after its botched launch of Aduhelm.
Alzheimer’s blockbuster might spur investor bonanza, higher medicare costs indiabusinessport.com
